Differential regulation of the apoptotic machinery during megakaryocyte differentiation and platelet production by inhibitor of apoptosis protein Livin

Cell Death and Disease

Volumn 4, Issue 11, 2013, Pages

  Abd Elrahman, I ^a   Deutsch, V ^b   Pick, M ^a   Kay, S ^b   Neuman, T ^a   Perlman, R ^a   Ben Yehuda, D ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Apoptosis; Inhibitor of apoptosis proteins; Livin; Megakaryocyte differentiation; Thrombopoiesis; tLivin

Indexed keywords

CASPASE 3; LIVIN; PHORBOL 13 ACETATE 12 MYRISTATE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MEGAKARYOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOCYTOPOIESIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD34; APOPTOSIS; BLOOD PLATELETS; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MEGAKARYOCYTES; NEOPLASM PROTEINS; RNA, SMALL INTERFERING;

EID: 84889567469     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.454     Document Type: Article

References (56)

1. Gordge MP. Megakaryocyte apoptosis: Sorting out the signals. Br J Pharmacol 2005; 145: 271-273
2. Ravid K, Lu J, Zimmet JM, Jones MR. Roads to polyploidy: The megakaryocyte example. J Cell Physiol 2002; 190: 7-20
3. Italiano JE, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999; 147: 1299-1312
4. Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: From bench to bedside. Br J Haematol 2013; 161: 778-793
5. Handagama PJ, Feldman BF, Jain NC, Farver TB, Kono CS. In vitro platelet release by rat megakaryocytes: Effect of metabolic inhibitors and cytoskeletal disrupting agents. Am J Vet Res 1987; 48: 1142-1146
6. Kile BT. The role of the intrinsic apoptosis pathway in platelet life and death. J Thromb Haemost 2009; 7: 214-217
7. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186
8. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14: 943-951
9. Clarke MCH, Savill J, Jones DB, Noble BS, Brown SB. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol 2003; 160: 577-587
10. de Botton S, Sabri S, Daugas E, Zermati Y, Guidotti JE, Hermine O, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002; 100: 1310-1317
11. Leytin V. Apoptosis in the anucleate platelet. Blood Rev 2012; 26: 51-63
12. Kaluzhny Y, Yu GG, Sun SS, Toselli PA, Nieswandt B, Jackson CW, et al. BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood 2002; 100: 1670-1678
13. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 2003 1999; 96: 14943-14948
14. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Kontgen F, et al. Proapoptotic Bcl-2 relative bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-1738
15. Sanz C, Benet L, Richard C, Badia B, Andreu EJ, Prosper F, et al. Antiapoptotic protein Bcl-x(L) is up-regulated during megakaryocytic differentiation of CD34() progenitors but is absent from senescent megakaryocytes. Exp Hematol 2001; 29: 728-735
16. Kozuma Y, Kojima H, Yuki S, Suzuki H, Nagasawa T. Continuous expression of Bcl-xL protein during megakaryopoiesis is post-Translationally regulated by thrombopoietinmediated Akt activation, which prevents the cleavage of Bcl-xL. J Thromb Haemost 2007; 5: 1274-1282
17. Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011; 208: 2017-2031
18. Morison IM, Cramer Borde EM, Cheesman EJ, Cheong PL, Holyoake AJ, Fichelson S, et al. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet 2008; 40: 387-389
19. White MJ, Schoenwaelder SM, Josefsson EC, Jarman KE, Henley KJ, James C, et al. Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood 2012; 119: 4283-4290
20. Winkler J, Rand ML, Schmugge M, Speer O. Omi/HtrA2 and XIAP are components of platelet apoptosis signalling. Thromb Haemost 2013; 109: 532-539
21. Du CY, Fang M, Li YC, Li L, Wang XD. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42
22. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53
23. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001; 8: 613-621
24. Hegde R, Srinivasula SM, Zhang ZJ, Wassell R, Mukattash R, Cilenti L, et al. Identification of Omi/HtrA-2as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem 2002; 277: 432-438
25. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-410
26. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Dataa P, Alnemri ES, et al. Structural basis of caspase-7 inhibition by XIAP. Cell 2000; 104: 769-780
27. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H. Structural basis of caspase inhibition by XIAP: Differential roles of the linker versus the BIR domain. Cell 2000; 104: 781-790
28. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): An emerging therapeutic target in cancer. Semin Cancer Biol 2004; 14: 231-243
29. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001; 495: 56-60
30. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000; 10: 1359-1366
31. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276: 3238-3246
32. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res 2003; 63: 6340-6349
33. Abd-Elrahman I, Hershko K, Neuman T, Nachmias B, Perlman R, Ben-Yehuda D. The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicity. Cancer Res 2009; 69: 5475-5480
34. Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci USA 2003; 100: 3398-3403
35. Cheng T, Wang YS, Dai W. Transcription factor egr-1 is involved in phorbol 12-myristate 13-Acetate-induced megakaryocytic differentiation of K562 cells. J Biol Chem 1994; 269: 30848-30853
36. Seigneurin D, Champelovier P, Mouchiroud G, Berthier R, Leroux D, Prenant M, et al. Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics. Exp Hematol 1987; 15: 822-832
37. Champelovier P, Valiron O, Michele J, Dominique L, Scigncurin D. Selection and characterization of an erythroeosinophilic subclone (LAMA-87) and an eosinophilic subclone (LAMA-88) from the multipotential cell line LAMA-84. Leuk Res 1994; 18: 903-918
38. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999; 18: 5242-5251
39. Nachmias B, Lazar I, Elmalech M, Abed-El-Rahaman I, Asshab Y, Mandelboim O, et al. Subcellular localization determines the delicate balance between the anti-And pro-Apoptotic activity of Livin. Apoptosis 2007; 12: 1129-1142
40. Pick M, Perry C, Lapidot T, Guimaraes-Sternberg C, Naparstek E, Deutsch V, et al. Stressinduced cholinergic signaling promotes inflammation-Associated thrombopoiesis. Blood 2006; 107: 3397-3406
41. Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 2003; 22: 8330-8336
42. Molla A, Berthier R, Chapel A, Schweitzer A, Andrieux A. Beta 1 integrins mediate adherent phenotype of human erythroblastic cell lines after phorbol 12-myristate 13-Acetate induction. Biochem J 1995; 309: 491-497
43. Gurbuxani S, Xu YF, Keerthivasan G, Wickrema A, Crispino JD. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci USA 2005; 102: 11480-11485
44. Cailleteau C, Liagre B, Beneytout JL. A proteomic approach to the identification of molecular targets in subsequent apoptosis of HEL cells after diosgenin-induced megakaryocytic differentiation. J Cell Biochem 2009; 107: 785-796
45. Lordier L, Jalil A, Aurade F, Larbret F, Larghero J, Debili N, et al. Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/ Rock signaling. Blood 2008; 112: 3164-3174
46. Wen Q, Leung C, Huang Z, Small S, Reddi AL, Licht JD, et al. Survivin is not required for the endomitotic cell cycle of megakaryocytes. Blood 2009; 114: 153-156
47. Boehm D, Mazurier C, Giarratana M-C, Darghouth D, Faussat A-M, Harmand L, et al. Caspase-3 is involved in the signalling in erythroid differentiation by targeting late progenitors. PLos One 2013; 8: 5
48. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Non-Apoptotic functions of apoptosisregulatory proteins. EMBO Rep 2012; 13: 322-330
49. Plenchette S, Cathelin S, Rebe C, Launay S, Ladoire S, Sordet O, et al. Translocation of the inhibitor of apoptosis protein c-IAPI from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: A nuclear export signal-mediated event. Blood 2004; 104: 2035-2043
50. Gyulkhandanyan AV, Mutlu A, Freedman J, Leytin V. Selective triggering of platelet apoptosis, platelet activation or both. Br J Haematol 2013; 161: 245-254
51. Lin KH, Chang HC, Lu WJ, Jayakumar T, Chou HC, Fong TH, et al. Comparison of the relative activities of inducing platelet apoptosis stimulated by various platelet-Activating agents. Platelets 2009; 20: 575-581
52. Cohen Z, Wilson J, Ritter L, McDonagh P. Caspase inhibition decreases both platelet phosphatidylserine exposure and aggregation-caspase inhibition of platelets. Thromb Res 2004; 113: 387-393
53. Vasina EM, Cauwenberghs S, Staudt M, Feijge MA, Weber C, Koenen RR, et al. Aging-And activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release. Am J Blood Res 2013; 3: 107-123
54. Kanamaru S, Kawano Y, Watanabe T, Nakagawa R, Suzuya H, Onishi T, et al. Low numbers of megakaryocyte progenitors in grafts of cord blood cells may result in delayed platelet recovery after cord blood cell transplant. Stem Cells 2000; 18: 190-195
55. Pick M, Nagler A, Grisaru D, Eldor A, Deutsch V. Expansion of megakaryocyte progenitors from human umbilical cord blood using a new two-step separation procedure. Br J Haematol 1998; 103: 639-650
56. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, et al. In vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-Thalassaemia major. Br J Haematol 1997; 98: 51-56